Joint venture aims to streamline handling of tissue and samples and subsequent digitization in support of clinical trial endpoint generation.
Clario, a healthcare research technology company, and CellCarta, an organization focused on integrated sample management and specialized laboratory services, have announced a strategic partnership aimed to improve clinical trial sample handling. Additionally, the companies hope to streamline the handling of tissue and samples and subsequent digitization in support of clinical trial endpoint generation across multiple therapeutic areas, including oncology, hepatology (e.g., NASH), and gastroenterology (e.g., UC and Crohn's).
"This collaboration brings together Clario's cutting-edge scientific expertise and unrivaled clinical trial endpoint solutions with CellCarta's unparalleled sample processing and management expertise," noted Joyce Suhy, PhD, EVP, medical imaging, and specialty solutions, Clario. "This partnership advances Clario's ability to support histopathology studies, providing our customers with full visibility for biopsy sample logistics and significantly accelerates delivery of centralized assessments for eligibility and efficacy endpoints."
Reference: Clario teams up with CellCarta to transform clinical trial sample management for histopathology studies. PR Newswire. September 26, 2023. Accessed September 27, 2023. https://www.prnewswire.com/news-releases/clario-teams-up-with-cellcarta-to-transform-clinical-trial-sample-management-for-histopathology-studies-301937860.html
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.